bluuebunny/crossref_metadata_2025_split huggingface dataset:
PB1769 INTERLEUKIN‐10 (1082G/A) GENE POLYMORPHISM IS ASSOCIATED WITH RISK OF ACUTE MYELOID LEUKEMIA IN SUDANESE POPULATION
Authors: Osman I. 
Published: June 2019

Background:Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous diseases, and description of transforming genetic events is becoming increasingly significant. Interleukins (ILs) are a diverse set of small cell signaling protein molecules. Single nucleotide polymorphisms (SNPs) of ILs alter their function, increasing predisposition to different illnesses.Aims:We investigated the association between a single nucleotide polymorphism (SNP) in IL‐10 ‐1082G/A (rs1800896) in Sudanese acute myeloid leukemia patientsMethods:A total of 30 patients with Acute Myeloid Leukemia and 30 control subjects were enrolled in this study. Blood samples were collected from all participants in EDTA containing tubes. Genomic DNA was extracted from all blood samples using salting out method. The genotypic variants of IL‐10(‐1082G/A) polymorphism were detected by allele specific‐PCR.Results:We found that (36.7%) of patients have homogenous GG genotype, (43.3%) have heterogeneous GA genotype and (20.0%) have AA genotype. GA genotype was significantly higher risk of AML compared with the homozygous, there is no association between IL‐10(‐1082G/A) polymorphism and AML sub‐type, gender, age group, mean of hematological parameter (TWBCs, Blast%, Hb and platelet count).Summary/Conclusion:In summary we conclude that GA genotype of IL‐10 ‐1082G/A (rs1800896) polymorphism is a risk factor for AML and G allele is insignificantly higher than A allele in AML patient. No association between IL‐10(‐1082G/A) polymorphism and AML sub‐type, gender, age group, mean of hematological parameter (TWBCs, Blast%, Hb and platelet count).
PB1778 ESTIMATION OF PROTEIN Z LEVEL IN ADULT NAÏVE ACUTE MYELOID LEUKEMIA PATIENTS
Authors: Mohamed H. , Hegab H. , El Razazz M. 
Published: June 2019

Background:The occurrence of various coagulation abnormalities in acute leukemia is well established, but there are no data assessing the role of protein Z (PZ), a vitamin K‐dependent plasma protein in hemostatic disorder in hematology cancers, including acute leukemia, The potential role of alterations of PZ levels in the pathogenesis of disorders of coagulation has been investigated and revealed conflicting results as Protein Z (PZ) deficiency may induce bleeding as well as thrombosis.Aims:to estimate the level of protein Z in Acute Myeloid Leukemia (AML) patients and its correlation with bleeding tendency or thrombosisMethods:PZ level was measured by ELISA kits in 60 adult naïve (AML) patients aged above 16 years old and 30 healthy controls after informed consent from Clinical Hematology Unit, Ain‐Shams University Hospital and correlated it with bleeding and thrombotic episodes. Patient on oral anti‐coagulant regularly, Inherited bleeding disorder, Inherited thrombophilia were excluded.Results:The median PZ level was lower in AML Patients in comparison to healthy controls{205ng/L (150 – 340) vs 349.5ng/L (274 – 400) with p value < 0.001}.No statistically significance correlation between protein Z level with initial platelet count(P value 0.323).
A statistically significant correlation was detected between episodes of bleeding and PZ level (P value 0.008). By utilizing ROC curve, the best cutoff value for protein Z as a predictor for bleeding episodes during induction was found >350ng/L.Summary/Conclusion:Conclusion: The results suggest that PZ level was lower in AML patients than healthy control and it was correlated with bleeding episodes. can be a cofactor associated with an increased bleeding tendency in AML patients.Summary: PZ can be a cofactor associated with an increased bleeding tendency in AML patients.
PB1783 PROGRAMMED CELL DEATH‐1 AND PROGRAMMED CELL DEATH LIGANDS EXPRESSION IN NODAL PERIPHERAL T‐CELL LYMPHOMA
Authors: Asawapanumas T. , Tungnantachai N. , Assanasen T. , Polprasert C. , Bunworasate U. , Intragumtornchai T. , Wudhikarn K. 
Published: June 2019

Background:Program cell death‐1/Program cell death ligands (PD‐1/PD‐Ls) is an important element of immune response regulation in human. Activation of PD‐1/PD‐Ls results in an inhibition of cellular mediated immune response. Several cancers including lymphoma exhibit abnormal PD‐1/PD‐Ls expression which may contribute to treatment failure and worse outcome. However, data of PD‐1/PD‐Ls expression in peripheral T cell lymphomas (PTCLs) has been sparsely described. Herein, we described expression patterns of PD‐1/PD‐Ls in PTCLs and explored their correlation with clinical parameters.Aims:To describe expression features of PD‐1/PD‐Ls in PTCLs and explore their correlation with clinical characteristics and outcomesMethods:We included 51 adult PTCLs diagnosed and followed up at King Chulalongkorn Memorial Hospital between 2550 and 2561. Medical records were abstracted for detailed clinical data. Paraffin embedded tissue archives were further stained for PD‐1, PD‐L1 and PD‐L2 which were independently interpreted for expression level and intensity by two hematopathologists. Membranous staining more than 5% was used as a positive cut off criteria. Correlation with clinical parameters was then analyzed.Results:Of 51 PTCLs, PD‐1, PD‐L1 and PD‐L2 were seen in 27.5%, 49.0% and 68.6% of PTCLs respectively. The expression patterns and frequency of PD‐1/PD‐Ls have varied among different histologic subtypes. There was no significant difference in baseline clinical characteristics between PD‐Ls expression status. With median follow up duration of 15 months, the 1‐year event free survival (EFS) and overall survival (OS) were 43.9 % and 61.6% respectively. Neither EFS nor OS was different among PD‐L1 or PD‐L2 expression cohort (1‐year EFS 39.3% in negative PD‐L1 lymphoma vs 46.9% in positive PD‐L1 lymphoma, 1‐year EFS 40.5% in negative PD‐L2 lymphoma vs 49.5% in positive PD‐L2 lymphoma) (1‐year OS 55.2% in PD‐L1 negative lymphoma vs 59.5% in PD‐L1 positive lymphoma, 1‐year OS 57.7% in PD‐L2 negative lymphoma vs 56.8% in PD‐L2 positive lymphoma). Univariate cox regression analysis showed that performance status was the only prognostic factor for survivals. PD‐1 and PD‐Ls expression status, either on lymphoma cells or non‐tumor stroma, were not predictive factors for treatment outcomes.Summary/Conclusion:Aberration expression of PD‐1/PD‐Ls could be seen in PTCLs and was varied among histologic subtypes. Clinical characteristics, treatment response and survivals were not statistically different among PD‐1 and PD‐Ls expression patterns.image
PB1799 HOW TO PREDICT EARLY PROGRESSION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
Authors: Nakaya A. , Ishii K. , Fujita S. , Satake A. , Nakanishi T. , Azuma Y. , Tsubokura Y. , Saito R. , Konishi A. , Hotta M. , Yoshimura H. , Ito T. , Nomura S. 
Published: June 2019

Background:Even in the rituximab era, the survival rates of patients who obtain complete remission and later experience disease recurrence remain unsatisfactory. The treatment strategy for early progression has not been taken into consideration.Aims:The aims of the present retrospective study were to extract DLBCL patients with early progression and to detect characteristic findings.Methods:530 patients diagnosed with DLBCL from April 2002 to November 2017 were enrolled in the study. Primary treatment included R‐CHOP or R‐CHOP‐like regimens. Early progression was defined as progressive disease or a transient response with disease progression within 6 months after completion of treatment.Results:Among 530 patients, 149 patients (28%) showed early progression. Survival of early progression patients were significantly worse (12.1 months vs 152.9 months, p = 3.26e‐66). In multivariate analysis, NCCN‐IPI, elevated LDH, and PS >3 were significant factors affecting survival. Patients who received salvage ASCT(n = 16) showed better prognosis than patients without ASCT (30.5 months vs 10.6 months, p = 0.012).Summary/Conclusion:In the rituximab era, we could use NCCN‐IPI to identify patients at high‐risk of early progression.image
PB1800 PROGNOSTIC RELEVANCE OF PROTEIN EXPRESSION, CLINICAL FACTORS, AND MYD88 MUTATION IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA
Authors: Xu Y. , zhou R. , Chen B. 
Published: June 2019

Background:Primary testicular diffuse large B‐cell lymphoma (tDLBCL) is a rare, clinically aggressive form of extranodal lymphoma confined to the testis. It is known to have a poor prognosis, with an outcome inferior to nodal DLBCL. Only a few studies of tDLBCL have included immunohistochemical and molecular investigations, and little is known about the prognostic significance of the in situ tissue antigen expression profiles in tDLBCL.Aims:We performed a mutation analysis of the MYD88 L265P mutation in 17 tDLBCL patients and investigated the immunophenotypic biomarkers and clinicopathological factors associated with tDLBCL.Methods:Clinical date and paraffin‐embedded material from 17 patients presenting with tDLBCL were retrieved from the archives of the pathology department at the Nanjing Drum Tower Hospital.Immunohistochemistry was used to examine the expression of CD10, Bcl2, Bcl6, MUM1, C‐myc, P50, P65, P53, PSTAT3, OCT4, PIM1, CXCR4 and JAK2. MYD88 gene mutation analysis and complete clinical data evaluation were carried out and linked to overall survival time.Results:High expression of B‐cell lymphoma 2 was detected in 7/17 tDLBCL patients and was associated with a poor prognosis in a univariate model. Most of these patients (6/7) also expressed c‐myc. P50, JAK2, PSTAT3, PIM1 and CXCR4 were also upregulated in tDLBCLs. There were seventeen cases of tDLBCL; in total, 82.4% (14/17) of patients exhibited an activated B‐cell‐like phenotype (ABC), 56.3% (9/16) of patients harbored the MYD88 L265P mutation and showed a correlation between the MYD88 L265P mutation and the ABC phenotype (p = 0.009). However, there was no association between the MYD88 mutation status and overall survival.Summary/Conclusion:We demonstrated that clinical factors such as age, IPI score, stage, lack of B symptoms and the over‐expression of Bcl‐2 are independent prognostic factors determining overall survival and that the over‐expression of P50, JAK2, PSTAT3, PIM1 and CXCR4 may promote the pathogenesis of tDLBCL. Moreover, we found a high prevalence of the MYD88 L265P mutation in tDLBCL, which may reflect a fairly consistent genetic feature in tDLBCL.
PB1802 INCREASED RISK OF HIP FRACTURES IN YOUNG WOMEN WITH LYMPHOMA, RESULTS FROM A SWEDISH POPULATION BASED STUDY
Authors: Johansson P. , Lewerin C. , Kristjansdottir H. , Johansson H. , Mellström D. 
Published: June 2019

Background:Blood cancer is the third most common cancer in Sweden and lymphoma is the most common of hematologic malignancies. A significant proportion of lymphoma patients are cured and others are living many years with disease. Bone loss has been noted in lymphoma patients. However, the incidence of fracture, the most devastating outcome of osteoporosis, and in particular hip fracture is not known in this group of patients.Aims:To determine the risk of hip fracture in patients with lymphoma diagnosed between 1995 and 2015Methods:We conducted a retrospective population based cohort study of Swedish lymphoma patients older than age 18 years, diagnosed from 1995 to the end of 2015 to determine the risk of hip fracture. Patients were identified from the National Cancer Register and from inpatient registers including all Swedish hospitals. They were followed up to 22 years (mean follow up 5.5 years). Fracture risk in lymphoma patients was compared with the Swedish population registry during the same time of period and adjusted for age, sex and calendar year.Results:37236 lymphoma patients were identified (45% women). 2.2 % of the men and 4.7% of women developed a hip‐fracture, in mean time 4.9 years after they were diagnosed with lymphoma. The incidence of hip‐fracture was higher in women than in men, increased by age and decreased by calendar year. The risk (hazard ratio‐HR) for hip fracture was increased in lymphoma patients compared with the Swedish general population, especially in younger women. The HR was 2.80 (95% CI 1.95‐4.03) in females aged 40 years in 2016 and for men corresponding HR was 1.70 (95% CI 1.44‐2.00). There was a trend to lower HR with increasing calendar year and older age. However, in elderly men (80 years of age) the risk for hip fracture was even lower, HR 0.83 (95% CI 0.81‐0.85) compared with the Swedish population. No differences between hip fracture incidence in patients with Hodgkin lymphoma or diffuse large B‐cell lymphoma compared with other lymphomas was noted (p>0.30). In multivariate analysis, unmarried men had a two times higher risk for hip‐fracture compared with men with other marital status with lymphoma (HR; 2.02 95% CI 1.63‐2.50).Summary/Conclusion:We conclude that lymphoma patients, especially younger women, are at higher risk of hip fracture than the general population independentlyimage
PB1807 RESULTS OF TREATMENT BY REGIMENS R‐MPV/TBC FOR PATIENTS WITH PRIMARY CNS LYMPHOMA
Authors: Zvonkov E. , Koroleva D. , Gabeeva N. , Smolyaninova A. , Gavrilina O. , Shchetsova O. , Gubkin A. , Kovrigina A. , Galstyan G. , Klyasova G. , Savenko T. , Parovichnikova E. , Savchenko V. 
Published: June 2019

Background:High‐dose MTX‐containing chemotherapy and autologous stem sell transplantation (HDC‐ASCT) is a potentially curable options for patients with primary central nervous system lymphoma (PCNCL). In our prospective study, pts with newly diagnosed PCNSL were treated with R‐MPV (rituximab, methotrexate, vincristine and procarbazine) chemotherapy, followed by consolidation HDC‐ASCT with TBC (thiotepa, busulfan and cyclophosphamide). After completion of therapy all pts reseived maintenance treatment with temozolomide every 3 months for a total of 2 years.Aims:To assess the efficacy and safety of regimens R‐MPV/TBC for patients with PCNSL.Methods:A total 19 pts were enrolled in prospective study between 2015 to 2019 years. The median age was 43 years (range, 20 to 62 years), with a total of 2 (10%) ≥ 60 years of age. Male:female = 13:7. In four pts (21%) the ECOG status was ≥ 2. The MSKCC prognostic class was as follows: 17 pts (91%), class 1; 2 pts (9%), class 2; 0 pts, class 3.Results:Following 3‐5 R‐MPV cycles 16 pts were in CR and 3 pts in PR. All pts were undegro stem‐sell harvest after the second cycle. All pts eventually received HDC‐ASCT with TBC. Treatment‐related mortality was 0%. All pts achieved haemotopoietic regeneration: the median times neutrophil and platelet recovery were 9 and 14 days, respectively. Seventeen pts are alive and well in complete remission at a median follow‐up of 12 months (range 1‐40). Two pts with progressive disease (+6 months) went on to received second‐line treatment: both had received chemotherapy and WBRT.Summary/Conclusion:Regimens R‐MPV/TBC was associated with favorable safety and high preliminary efficacy.
PB1817 A STUDY OF SERUM ALBUMIN AND CALCIUM IN 93 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Authors: Gao X. , Qiu H. , Wang J. , Duan L. , Tian T. 
Published: June 2019

Background:Hemophagocytic lymphohistiocytosis is a fatal syndrome of overactive inflammation, which is caused by excessive cytokines released by abnormal cytotoxic T cells, NK cells and macrophages. According to the etiology, it can be divided into primary HLH and secondary HLH.Aims:To investigate the clinical significance of serum albumin levels and calcium concentrations in patients with secondary hemophagocytic lymphohistiocytosis.Methods:The clinical and laboratory data of 93 patients with newly diagnosed sHLH in 2013.4 to 2017.5, and 20 healthy controls were retrospectively analyzed. The patients were classified as the clinical remission group and the progression group according to the response criteria. To explore the changes of serum calcium concentrations and albumin levels in the patients, its correlations with other laboratory indexes and the impact on survival.Results:(1) The serum calcium concentrations and albumin levels in lymphoma‐related HLH group and non‐tumor HLH group were lower than control group (P < 0.001); The serum calcium concentrations and albumin levels in the clinical remission group after treatment was higher than that before treatment (P < 0.001), while in the progression group the serum calcium concentrations and albumin levels after treatment did not changed significantly (P > 0.05,P = 0.101). (2) The serum calcium concentrations in newly diagnosed sHLH patients was positively correlated with ANC, PLT, HGB (P < 0.05); The overall survival (OS) was significantly longer in patients with serum calcium concentration ≥1.88 mmol/L than that<1.88 mmol/L (P = 0.006). (3) The serum albumin levels in newly diagnosed sHLH patients was positively correlated with ANC, HGB (P < 0.05); The overall survival was longer in patients with serum albumin level ≥25.2 g/L than that<25.2 g/L (P = 0.005).Summary/Conclusion:The serum calcium concentrations and albumin levels have clinical significance for disease diagnosis, decision‐making therapy and treatment outcomes in the patients with sHLH.
PB1818 CLINICAL FEATURES AND PROGNOSTIC FACTORS OF PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA (PT‐DLBCL): EXPERIENCE OF 35 PATIENTS FROM FUSCC
Authors: Liu Y.‐Z. , Luo P. , Zhang Q.‐L. , Xue K. , Cao J.‐N. , Hong X.‐N. , Lv F.‐F. 
Published: June 2019

Background:Primary testicular lymphoma (PTL) is a rare extranodal lymphoma, with diffuse large B cell lymphoma (DLBCL) as the predominant histological subtype. Factors that contribute to precise stratification and guide the treatment of this disease are still not well understood.Aims:This study aims to identify clinical features and prognostic factors of PT‐DLBCL patients.Methods:A total of 35 patients were included in this retrospective study who were diagnosed as PT‐DLBCL and treated in Shanghai Cancer Center, China from March 2007 to May 2018. The demographic details, clinico‐pathologic characteristics of the patients were summarized. Kaplan‐Meier survival curves were constructed for survival analyses.Results:The median age of the patients was 59 (range 36‐76) years old. All patients presented with testicular swelling, two had the presence of B symptoms. 33(94%) patients underwent orchiectomy. All patients received combination chemotherapy for 4‐6 cycles and central nervous system prophylaxis consisting of MTX for 4‐6 doses. 87% (28/32) patients achieved complete response, and ORR was 96.9% (31/32). 21 patients continued contralateral testis irradiation in our hospital. The median follow‐up time was 980 days (range 156‐2976 days). Median overall survival (OS) was not reached at the time of reporting. The estimated 5‐year PFS and OS rate were 67% and 84%. None of the 21 patients who received radiotherapy to the contralateral testis experienced relapse in that location in our study. All three patients who suffered from central nervous system relapse had the germinal center B‐cell subtype of DLBCL. Kaplan‐Meier analysis showed that PT‐DLBCL patients characterized by late stage (Stage III/IV) (P = 0.003), higher IPI score (IPI≥ 2) (P = 0.001) had a shorter progression free survival (PFS). More importantly, we found that patients with the ratio of the LDH level in CSF to the serum LDH level more than 6.5 suffered from a worse PFS (P = 0.032).Summary/Conclusion:Our work revealed that staging III/IV, IPI score ≥ 2 were adverse factors of PT‐DLBCL patients’ PFS. Significantly, the PT‐DLBCL patients with ratio of LDH level in CSF to the serum LDH level > 6.5 were indicated to have a worse PFS.
PB1830 CLINICAL IMPACTS OF INFLAMMATORY MARKERS IN PATIENTS WITH LIMITED STAGE UPPER AERODIGESTIVE TRACT NK/T CELL LYMPHOMA
Authors: Chung J.‐S. , Kim D.‐Y. , Song M.‐K. , Joo Y.‐D. 
Published: June 2019

Background:In localized extranodal natural killer/T cell lymphoma (ENKTCL), traditional prognostic models had a limited prognostic value to predict survivals. Especially, clinical data is limited to find out what the most meaningful inflammatory marker among them is and determine whether the meaningful inflammatory marker would be useful to reinforce prognostic limitations of the traditional prognostic models in ENKTCLAims:The present study was performed to find out the most meaningful factor among available inflammatory markers and to evaluate whether the inflammatory marker would improve predictive ability of traditional models in patients with limited stage UAT ENKTCL.Methods:We evaluated prognostic value of inflammatory makers in 157 patients with limited stage upper aerodigestive tract (UAT) ENKTCL. Diagnosis of ENKTCL was according to the presence of histologic findings and immunophenotypes such as CD3+, CD20‐, CD56+ and positive Epstein‐barr virus by fluorescence in situ hybridization.Statistical Analysis
Chi‐square test or Fisher's exact test were used as appropriate to analyze categorical variables. Progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan‐Meier method and the 2‐tailed log‐rank test. PFS was defined as the time between the beginning of salvage therapy until disease progression or death. Meanwhile, OS was defined as the time from the start of salvage therapy until death. Cox proportional hazard model was used to evaluate prognostic impacts of several prognostic factors. Hazard ratios (HRs) of prognostic factors were used to measure the differential risks of progression and death. Receiver operating characteristic (ROC) curves were prepared to estimate the accuracy of predicting the ideal cut‐off values of continuous variables. The statistical analysis was carried out with SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA). A p‐value < 0.05 was considered significant.Results:Among several inflammatory markers, mean platelet volume (MPV) was most meaningful predictive value for progression‐free survival (PFS) and overall survival (OS). Ideal cut‐off value of MPV was 8.8 in Receiver operating characteristic analysis. In univariate and multivariate analysis, only two factors such as low MPV (< 8.8) (PFS, HR = 2.483, 95% CI = 1.182‐4.601, p = 0.009; OS, HR = 3.412, 95% CI = 1.949‐6.990, p = 0.008) and high international prognostic index (IPI) score (IPI ≥ 2) (PFS, HR = 3.339, 95% CI = 1.323‐8.430, p = 0.011; OS, HR = 3.317, 95% CI = 1.046‐6.892, p = 0.010) were significantly associated with both PFS and OS. interestingly, the MPV value could significantly subdivide low IPI score group (PFS, p = 0.006; OS, p = 0.021).Summary/Conclusion:We found that Low MPV and high IPI can significantly predict poor prognosis in localized ENKTCL.image